Journal Der Deutschen Dermatologischen Gesellschaft最新文献_第4页

Regional variations and temporal trends of atopic diseases in Germany. 德国特应性疾病的地区差异和时间趋势。

IF 3.8 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-05-01 Epub Date: 2026-01-16 DOI: 10.1111/ddg.15926

Marie Sander, Matthias Augustin, Valerie Andrees, Sandra Hischke, Jobst Augustin

{"title":"Regional variations and temporal trends of atopic diseases in Germany.","authors":"Marie Sander, Matthias Augustin, Valerie Andrees, Sandra Hischke, Jobst Augustin","doi":"10.1111/ddg.15926","DOIUrl":"10.1111/ddg.15926","url":null,"abstract":"Background and objectives: Prevalence rates of atopic diseases (atopic dermatitis [AD], allergic asthma [AA], and allergic rhinoconjunctivitis [ARC]) have increased in Germany. However, there is a lack of simultaneous consideration and of precise data on the spatiotemporal variation of these diseases. This study investigates the spatiotemporal variation of atopic diseases in Germany.Methods: Analyses based on outpatient care data (2011-2020) of all statutory health insured persons in Germany. Spatiotemporal analyses of prevalence rates were performed on county levels and statistical smoothing were applied.Results: Prevalence rates increased for all three diseases. Moderate but significant (p < 0.05) correlations were among others observed between ARC and AA (r = 0.47). Correlations with the east-west gradient were significant for all diseases, meaning higher prevalence rates of AD in the east and higher prevalence rates of AA and ARC in the west. The correlation coefficients showed significant values between the north-south gradient and AD, as well as between the north-south gradient and AA, implying higher prevalences in northern Germany.Conclusions: Prevalence rates for atopic diseases have increased over the past decade. Regional patterns are different for AD and the other atopic diseases. The reasons for the increase and the variations need to be analysed in detail with a view to improving prevention and health care.","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":"634-641"},"PeriodicalIF":3.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13140137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145989177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Garadacimab for the long-term prophylaxis of hereditary angioedema. 加拉达昔单抗长期预防遗传性血管性水肿。

IF 3.8 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-04-30 DOI: 10.1111/ddg.70276

Emel Aygören-Pürsün, Regina Treudler, Petra Staubach, Inmaculada Martinez Saguer, Thomas Linhoff, Markus Magerl

{"title":"Garadacimab for the long-term prophylaxis of hereditary angioedema.","authors":"Emel Aygören-Pürsün, Regina Treudler, Petra Staubach, Inmaculada Martinez Saguer, Thomas Linhoff, Markus Magerl","doi":"10.1111/ddg.70276","DOIUrl":"https://doi.org/10.1111/ddg.70276","url":null,"abstract":"Hereditary angioedema (HAE), a rare and debilitating disease characterized by recurrent and spontaneous attacks of tissue swelling, has a high unmet therapeutic need, with many patients experiencing insufficient disease control with current prophylactic treatments. The goal of HAE treatment as per guidelines is to achieve total disease control and to normalize patients' lives. Factor XII (FXII), the principal initiator of the contact system, ultimately regulates the kallikrein-kinin system. Activated FXII (FXIIa) converts plasma prekallikrein to plasma kallikrein, which cleaves high-molecular-weight kininogen to produce the vasoactive peptide bradykinin. In HAE pathophysiology, kallikrein-kinin system dysregulation results in excessive bradykinin production. The anti-FXIIa monoclonal antibody garadacimab is approved for long-term prophylaxis against HAE attacks. In the pivotal phase III (VANGUARD) and ongoing phase III open-label extension studies, garadacimab administered subcutaneously (2 × 200 mg loading dose followed by 200 mg once monthly) demonstrated durable efficacy with early onset of protection and a favorable long-term safety profile. Based on this and earlier clinical data, garadacimab has the potential to bring patients closer to achieving the guideline-recommended goals of disease control and normalization of life. Here, we provide an overview of the results from the garadacimab clinical development program.","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147771904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A solitary reddish nodule on the chest of a 36-year-old woman. 36岁女性胸部单发红色结节。

IF 3.8 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-04-29 DOI: 10.1111/ddg.70311

Yin Lv, Yuelin Li, Jian Li, Yingying Xiang, Hong Ren, Renqiong Chen

引用次数: 0

Cold plasma treatment for oral lichen planus: a retrospective case collection and proposal of a new clinical score. 冷等离子体治疗口腔扁平苔藓：回顾性病例收集和新的临床评分建议。

IF 3.8 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-04-29 DOI: 10.1111/ddg.70193

Christian Seebauer, Hans-Robert Metelmann, Mohamed Falougy, Wolfram Kaduk, Lasse Kremer, Georg Daeschlein

{"title":"Cold plasma treatment for oral lichen planus: a retrospective case collection and proposal of a new clinical score.","authors":"Christian Seebauer, Hans-Robert Metelmann, Mohamed Falougy, Wolfram Kaduk, Lasse Kremer, Georg Daeschlein","doi":"10.1111/ddg.70193","DOIUrl":"https://doi.org/10.1111/ddg.70193","url":null,"abstract":"Background and objectives: Oral lichen planus (OLP) is a chronic autoimmune mucosal disease with malignant potential and limited treatment options. This study evaluated the long-term efficacy and safety of cold atmospheric plasma (CAP) therapy in therapy-refractory OLP and introduced the novel Lichen Planus Severity Score (LPSS).Patients and methods: Between 2016 and 2019, four patients with histologically confirmed erosive or reticular OLP unresponsive to standard treatments received intraoral CAP therapy using an Argon-based plasma device. Disease activity and symptoms were systematically assessed using the LPSS, integrating clinician-rated (inflammation, ulceration) and patient-reported (pain, function) parameters. Follow-up extended up to 9 years.Results: All patients achieved significant clinical improvement, with LPSS grades decreasing from II-III to I post-therapy. CAP treatment showed a strong, statistically significant correlation with reduced inflammation, ulceration, symptoms, and total LPSS (p < 0.001; ρ = -0.34 to -0.96), indicating sustained remission. No adverse effects or malignant transformations occurred during follow-up.Conclusions: This first long-term evaluation demonstrates that CAP therapy provides durable remission and excellent safety in refractory OLP. The LPSS proved practical for standardized monitoring. CAP represents a promising non-immunosuppressive therapeutic option warranting validation in larger controlled studies.","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147771833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficient triage and improved patient care: Five years of teledermatology in Styria. 有效的分诊和改进的病人护理：Styria的5年远程皮肤科。

IF 3.8 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-04-23 DOI: 10.1111/ddg.70097

Arzberger Edith, Bordag Natalie, Hofmann-Wellenhof Elena, Freytag Leo, Hofmann-Wellenhof Rainer

{"title":"Efficient triage and improved patient care: Five years of teledermatology in Styria.","authors":"Arzberger Edith, Bordag Natalie, Hofmann-Wellenhof Elena, Freytag Leo, Hofmann-Wellenhof Rainer","doi":"10.1111/ddg.70097","DOIUrl":"https://doi.org/10.1111/ddg.70097","url":null,"abstract":"Background: To improve dermatological care in underserved rural regions, the \"Teledermatology in Styria\" project launched on January 1st, 2020. General practitioners (GP) were digitally connected with dermatologists (DERM), supported by Styrian Health Fund, Styrian Medical Association, Austrian Health Insurance Fund Styria, Universities' Department of Dermatology, and e-derm-consult GesmbH.Patients and methods: GPs submit clinical information and images (clinical, dermoscopic) of patient's skin conditions, via a \"store-and-forward\" service to DERM, who responded with diagnosis and treatment recommendations. The descriptive statistical analysis covered cases from five years without reference region and assessed patient and doctor acceptance through questionnaires.Results: From 5,119 cases DERM changed GPs diagnosis in 51%, no diagnosis was provided by GPs in 23% and only in 25% DERM confirmed GPs diagnosis. While 19% of all cases required no therapy, most cases (61%) were managed by their GPs following teledermatological consultation. Referrals included 12% routine dermatological appointments, 3% urgent appointments, and 2% hospital visits. The case spectrum covered all dermato-venereological conditions, with only 34% neoplasms. Patient satisfaction exceeded 95%, based on 692 returned questionnaires.Conclusions: Only 17% of patients required additional dermatological examination after teledermatology. The months faster diagnosis and the high level of patient satisfaction highlight the benefits of teledermatological consultations.","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147771867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and validation of the Essen Melanoma Quality of Life Inventory (EMQoLI). Essen黑色素瘤生活质量量表（EMQoLI）的开发和验证。

IF 3.8 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-04-20 DOI: 10.1111/ddg.15998

Venja Musche, Theresa Schadendorf, Adam Schweda, Georg Lodde, Jessica Neumann, Lisa Zimmer, Svea Hüning, Dirk Schadendorf, Eva-Maria Skoda, Elisabeth Livingstone, Martin Teufel

{"title":"Development and validation of the Essen Melanoma Quality of Life Inventory (EMQoLI).","authors":"Venja Musche, Theresa Schadendorf, Adam Schweda, Georg Lodde, Jessica Neumann, Lisa Zimmer, Svea Hüning, Dirk Schadendorf, Eva-Maria Skoda, Elisabeth Livingstone, Martin Teufel","doi":"10.1111/ddg.15998","DOIUrl":"10.1111/ddg.15998","url":null,"abstract":"Background and objectives: New treatments for melanoma, such as targeted therapy and immunotherapy, present unique adverse events compared to traditional treatments like surgery and chemotherapy. Existing health-related quality of life (HRQoL) measures often fail to address these new treatment effects and focus primarily on chemotherapy and surgery. This study aimed to develop and validate a new HRQoL instrument for melanoma patients across all tumor stages, encompassing a broader range of adverse events and melanoma-specific aspects.Patients and methods: The Essen Melanoma Quality of Life Inventory (EMQoLI) was tested with 387 German-speaking malignant melanoma patients across all tumor stages.Results: Exploratory factor analysis revealed a three-factor structure. Eight items were removed due to low or cross-loading, leaving a final version of 25 items with satisfactory reliability and internal consistency. Correlation analyses indicated good convergent and discriminant validity.Conclusions: The EMQoLI is a 25-item German self-report tool based on a 5-point Likert scale, designed to assess HRQoL in melanoma patients across all tumor stages. It offers healthcare professionals an efficient tool to identify patients needing psychosocial support and can serve as a standardized measurement instrument in clinical settings.","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Attitudes of dermatological patients towards digital health interventions: a cross-sectional survey and cluster analysis. 皮肤科患者对数字健康干预的态度：横断面调查和聚类分析。

IF 3.8 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-04-16 DOI: 10.1111/ddg.70010

Patrick Reinders, Matthias Augustin, Marina Otten

{"title":"Attitudes of dermatological patients towards digital health interventions: a cross-sectional survey and cluster analysis.","authors":"Patrick Reinders, Matthias Augustin, Marina Otten","doi":"10.1111/ddg.70010","DOIUrl":"https://doi.org/10.1111/ddg.70010","url":null,"abstract":"Background: This study aimed to assess the acceptance of Germany's adoption of digital health interventions (DHI) among dermatology patientsand to identify patient clusters.Patients and methods: A cross-sectional, quantitative survey on acceptability and (future) usage of DHIs was conducted among patients with chronic dermatological conditions. Exploratory Factor Analysis (EFA) identified key constructs and patients were grouped using a two-step clustering approach.Results: The EFA was conducted using data from 344 patients (mean age 52.5 years, SD 14.8; 74.0 % female) and identified four factors: \"Acceptability of DHIs and Trust,\" \"Patients' Digital Health Competencies,\" \"Digital Health Insecurities,\" and \"Positive Impact of DHIs.\" Cluster analysis resulted in four groups: \"Digital Sceptics\" (n = 49, 15.6 %), \"Cautious Adopters\" (n = 106, 33.7 %), \"Digital Enthusiasts\" (n = 98, 31.1 %), \"Adopters Unsure About Impact\" (n = 62, 18.0 %). \"Digital Enthusiasts\" were significantly younger. Usage and acceptability varied among clusters, with \"Digital Enthusiasts\" and \"Adopters Unsure About Impact\" showing the highest rates. Overall, few patients used DHIs, including store-and-forward teledermatology (2.0 %-7.0 %) or electronic patient records (6.4 %-19.4 %).Conclusions: Patient clusters with varying attitudes towards DHIs were identified. Despite a general willingness to adopt DHIs, actual usage remains low. Systemic barriers such as availability and digital competencies need to be addressed.","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147690166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sonidegib efficacy and safety in ultra-nonagenarian patients. 索尼地吉在超高龄患者中的疗效和安全性。

IF 3.8 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-04-16 DOI: 10.1111/ddg.70307

Camilla Brunello, Andrea Corio, Marco Zanette, Raffaele Dante Caposiena Caro, Iris Zalaudek, Nicola di Meo

引用次数: 0

Safety of biologic therapy in psoriasis patients with a previous malignancy: Retrospective study using TriNetX. 既往恶性肿瘤银屑病患者生物治疗的安全性：TriNetX回顾性研究

IF 3.8 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-04-14 DOI: 10.1111/ddg.70051

Alfonso Gotor-Rivera, Julia Hernández-Sánchez, Eva Chamorro-Jiménez, Emilia García-Rivera, Pablo Ortiz-Romero, Carmen García-Donoso, Raquel Rivera-Díaz

{"title":"Safety of biologic therapy in psoriasis patients with a previous malignancy: Retrospective study using TriNetX.","authors":"Alfonso Gotor-Rivera, Julia Hernández-Sánchez, Eva Chamorro-Jiménez, Emilia García-Rivera, Pablo Ortiz-Romero, Carmen García-Donoso, Raquel Rivera-Díaz","doi":"10.1111/ddg.70051","DOIUrl":"https://doi.org/10.1111/ddg.70051","url":null,"abstract":"Background and objectives: Evidence-based recommendations for the treatment of patients with psoriatic disease (PsO) and a prior history of malignancy are limited. This study aimed to compare the incidence of newly diagnosed neoplasms among patients with PsO and a previous malignancy receiving treatment with conventional systemic therapies, apremilast, or biologic agents.Patients and methods: Retrospective observational study using TriNetX. PsO patients (ICD10:L40) with a previous diagnosis of cancer (ICD10:C00-D49) less than 5 years prior to systemic therapy initiation were selected. Outcomes evaluated included new documentation of neoplasms and all-cause mortality.Results: Patients under biologic therapy had a significantly lower new neoplasm documentation rate and all-cause mortality compared to classical agents (HR 0.857 and HR 0.705, respectively) and apremilast (HR 0.782 and HR 0.803, respectively) at 3 years follow-up. Only TNFi exhibited a significantly lower new neoplasm rate (HR 0.867, p < 0.0001) compared to classical agents; however, all biologic agents significantly decreased mortality. IL-23i was the only biologic therapy to significantly lower cancer recurrence risk (RR 0.878) compared to TNFi, with no differences in all-cause mortality.Conclusions: Biologic therapy for PsO may represent a safe treatment option in patients with a history of malignancy, compared with conventional systemic therapies or apremilast. Among biologic agents, IL-23 inhibitors appear to be associated with the most favorable safety profile.","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147673638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Congenital aleukemic leukemia cutis mimicking infantile hemangioma. 模仿婴儿血管瘤的先天性白血病。

IF 3.8 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-04-13 DOI: 10.1111/ddg.70305x

Ana Clara Maia Palhano, Fábio Augusto Peroni Garcia, Thais Kohatsu Yanase, Luciana Paula Samorano, Maria Cecilia Rivitti-Machado, Zilda de Najjar Prado Oliveira

引用次数: 0